Mark Neumann - Intracellular Executive Vice President Chief Commercial Officer
| ITCI Stock | USD 85.69 0.24 0.28% |
President
Mr. Mark Neumann is Executive Vice President, Chief Commercial Officer of the Company. Mr. Neumann has served as Executive Vice President, Chief Commercial Officer of the Company since October 2018. From June 2014 to October 2018, Mr. Neumann served in leadership positions at Amgen, most recently serving as Vice President, Global Marketing. Before Amgen, from February 2014 to June 2014 Mr. Neumann served in a leadership position at AstraZeneca. Before joining AstraZeneca, from June 1988 to February 2014, he served at Bristol Myers Squibb Company in positions of increasing responsibility, including commercial leadership roles since 2018.
| Age | 61 |
| Tenure | 6 years |
| Professional Marks | CPA |
| Address | 430 East 29th Street, New York, NY, United States, 10016 |
| Phone | 646 440 9333 |
| Web | https://www.intracellulartherapies.com |
Latest Insider Transactions
Neumann is a licensed CPA and received his bachelor’s degree from Lafayette College.Mark Neumann Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Neumann against Intracellular stock is an integral part of due diligence when investing in Intracellular. Mark Neumann insider activity provides valuable insight into whether Intracellular is net buyers or sellers over its current business cycle. Note, Intracellular insiders must abide by specific rules, including filing SEC forms every time they buy or sell Intracellular'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Neumann over three months ago Disposition of 18714 shares by Mark Neumann of Intracellular at 36.89 subject to Rule 16b-3 | ||
Mark Neumann over six months ago Disposition of 4059 shares by Mark Neumann of Intracellular at 69.56 subject to Rule 16b-3 |
Intracellular Management Efficiency
The company has return on total asset (ROA) of (0.0745) % which means that it has lost $0.0745 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.099) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.2. The current Return On Capital Employed is estimated to decrease to -0.28. As of now, Intracellular's Non Currrent Assets Other are increasing as compared to previous years. The Intracellular's current Deferred Long Term Asset Charges is estimated to increase to about 635.1 K, while Total Assets are projected to decrease to under 410.9 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Joseph Todisco | Amneal Pharmaceuticals, Class | 45 | |
| David Gaffin | Alkermes Plc | 52 | |
| Nikita Shah | Amneal Pharmaceuticals, Class | 45 | |
| Andrew Boyer | Amneal Pharmaceuticals, Class | 58 | |
| Michael Ostrach | Dynavax Technologies | 72 | |
| Daniel Barber | Aquestive Therapeutics | 48 | |
| Sanjay Jain | Amneal Pharmaceuticals, Class | N/A | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
| Stephen Carey | ANI Pharmaceuticals | 53 | |
| Stephen Manzano | Amneal Pharmaceuticals, Class | 55 | |
| Peter Boyd | Aquestive Therapeutics | 58 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Anastasios Konidaris | Amneal Pharmaceuticals, Class | 57 | |
| Joseph Greer | Amneal Pharmaceuticals, Class | N/A | |
| Ryan Spencer | Dynavax Technologies | 46 | |
| Michael Landine | Alkermes Plc | 70 | |
| Robert Janssen | Dynavax Technologies | 70 | |
Management Performance
| Return On Equity | -0.099 | ||||
| Return On Asset | -0.0745 |
Intracellular Th Leadership Team
Elected by the shareholders, the Intracellular's board of directors comprises two types of representatives: Intracellular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intracellular. The board's role is to monitor Intracellular's management team and ensure that shareholders' interests are well served. Intracellular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intracellular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO, Fin | ||
| Robert Davis, Senior Vice President and Chief Scientific Officer | ||
| Suresh MD, Executive Officer | ||
| Mark Neumann, Executive Vice President Chief Commercial Officer | ||
| Karen Esq, Senior Officer | ||
| Willie MD, Senior Development | ||
| Sharon Mates, Co-Founder, Chairman, CEO and Pres | ||
| Michael JD, General VP | ||
| Juan Sanchez, Vice President - Corporate Communications and Investor Relations | ||
| John Bardi, Senior Vice President - Market Access, Policy and Government Affairs | ||
| Lawrence CPA, CFO, Finance | ||
| John Condon, General President | ||
| Michael Olchaskey, Senior Vice President Head of Regulatory Affairs |
Intracellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intracellular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.099 | ||||
| Return On Asset | -0.0745 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 8.1 B | ||||
| Shares Outstanding | 106.02 M | ||||
| Shares Owned By Insiders | 2.33 % | ||||
| Shares Owned By Institutions | 96.01 % | ||||
| Number Of Shares Shorted | 2.36 M | ||||
| Price To Earning | (6.56) X |
Currently Active Assets on Macroaxis
When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 6.096 | Quarterly Revenue Growth 0.39 | Return On Assets (0.07) | Return On Equity (0.1) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.